TRAX MEXC RealStocks
Own real TRAX shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1

Last updated: 2026-11-19 07:41:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
First Tracks Biotherapeutics, Inc. (TRAX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $44.49, with a market capitalization of $1.83B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $14.72 to $54.78. This page covers its latest market performance, valuation, price trends and company information.
$1.83B | |
$43.17 | |
$45.33 | |
$43.13 | |
$43.57 | |
677.89K | |
833.44K | |
-- | |
$54.78 | |
$14.72 | |
-- | |
2026-09-30 |
First Tracks Biotherapeutics, Inc. (TRAX) last closed at $44.49 as of 2026-11-19 00:56:00, up 2.13% ($0.93) from the previous close of $43.57.
During the latest regular trading session, TRAX traded between $43.13 and $45.33, with a volume of 677.89K shares. The closing price was near the middle and near the upper end of its 52-week range.
Over the past seven days, First Tracks Biotherapeutics, Inc. (TRAX) moved from $52.33 to $44.49, representing a decline of 14.99% ($7.84).
The stock traded between $43.06 and $54.78 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 598.58 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 74.3%
TRAX is currently trading at $44.49, placing it 74.3% of the way from its 52-week low of $14.72 to its 52-week high of $54.78. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Exchange | NASDAQ |
Eligible investors can buy real shares of First Tracks Biotherapeutics, Inc. (TRAX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to TRAX, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between TRAX shares and USD.
TRAX Shares to USD
1.00 TRAX shares = 44.485 USD
Calculations are estimates based on the latest available price and are for reference only.